place

Gustav Stresemann Business School

Buildings and structures in Mainz

The GSW (Gustav-Stresemann-Wirtschaftsschule) is a German high school in Mainz. Mainz is the capital of Rhineland-Palatinate. The school is situated between the station Mainz Römisches Theater and the industrial area of the city. It is named after Gustav Stresemann, the liberal politician and statesman.

Excerpt from the Wikipedia article Gustav Stresemann Business School (License: CC BY-SA 3.0, Authors).

Gustav Stresemann Business School
Hechtsheimer Straße, Mainz Oberstadt (Oberstadt)

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: Gustav Stresemann Business SchoolContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 49.981138888889 ° E 8.2776388888889 °
placeShow on map

Address

Hechtsheimer Straße 31
55131 Mainz, Oberstadt (Oberstadt)
Rhineland-Palatinate, Germany
mapOpen on Google Maps

Share experience

Nearby Places

BioNTech
BioNTech

BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Some days later the vaccine also received an emergency approval in the United States, Canada and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).